Get the Stockscreener App
0.8604
6.13%
0.0497
After Hours:
.84
-0.0204
-2.37%
Shattuck Labs Inc stock is traded at $0.8604, with a volume of 514.24K.
It is up +6.13% in the last 24 hours and up +4.93% over the past month.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
See More
Previous Close:
$0.8107
Open:
$0.8
24h Volume:
514.24K
Relative Volume:
0.30
Market Cap:
$41.22M
Revenue:
$2.72M
Net Income/Loss:
$-85.08M
P/E Ratio:
-0.4458
EPS:
-1.93
Net Cash Flow:
$-70.93M
1W Performance:
+10.18%
1M Performance:
+4.93%
6M Performance:
-35.31%
1Y Performance:
-72.42%
1-Day Range:
$0.7877
$0.874
1-Week Range:
$0.712
$0.874
52-Week Range:
$0.6922
$3.95
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
0.8604 | 38.84M | 2.72M | -85.08M | -70.93M | -1.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.30 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.97 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.73 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.43 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.69 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
Shattuck Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Shattuck Labs stock price target lowered to $2 by Leerink Partners - Investing.com Canada
Shattuck Labs: A Narrowing Loss and Strategic Milestones Signal a Pivotal Turn for Biotech Investors - AInvest
Shattuck Labs Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Shattuck Labs, Inc. SEC 10-Q Report - TradingView
Shattuck Labs Submits IND Application for SL-325; Phase 1 Trial in Healthy Volunteers Expected to Begin Q3 2025 - Quiver Quantitative
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Shattuck Labs Advances First-in-Class IBD Treatment as $103M Funding Extends Runway to 2029 - Stock Titan
Will Shattuck Labs Inc. see short term momentumDay Trade & Expert Approved Trade Ideas - Newser
Is now a turning point for Shattuck Labs Inc.Weekly Trend Summary & AI Forecasted Stock Moves - Newser
Tools to assess Shattuck Labs Inc.’s risk profileTrade Volume Summary & Detailed Earnings Play Strategies - Newser
How to recover losses in Shattuck Labs Inc. stockTrade Signal Summary & Safe Capital Investment Plans - Newser
Published on: 2025-08-13 05:02:56 - Newser
Tick level data insight on Shattuck Labs Inc. volatilityEarnings Recap Report & Verified Chart Pattern Trade Signals - Newser
What momentum shifts mean for Shattuck Labs Inc. [2025 Market Overview]High Accuracy Trade Signal Alerts - Newser
Advanced analytics toolkit walkthrough for Shattuck Labs Inc.Market Activity Report & Long-Term Safe Investment Plans - Newser
What momentum shifts mean for Shattuck Labs Inc.Swing Trade Signal and Price Prediction - Newser
Is Shattuck Labs Inc. meeting your algorithmic filter criteriaDaily Trade Setup Forecast with Confidence - Newser
Citizens & Northern Corp Director Katherine W Shattuck Buys 20 Shares - AInvest
Will Shattuck Labs Inc. stock recover after recent dropHistorical Market Behavior and Trend Summary - Newser
Will a bounce in Shattuck Labs Inc. offer an exitWeekly Trend Screener with Momentum Picks - Newser
Can you recover from losses in Shattuck Labs Inc.7-Day Equity Return Range Forecast Model - Newser
Using portfolio simulators with Shattuck Labs Inc. includedMomentum Trading Guide with Safety Limits - Newser
Real time breakdown of Shattuck Labs Inc. stock performanceTrading Opportunities Forecast by AI Insight - Newser
Momentum divergence signals in Shattuck Labs Inc. chartMarket Sentiment Tracker with Smart Alerts - Newser
Can Shattuck Labs Inc. recover in the next quarterFree Swing Setup With Technical Confirmation - Newser
Will Shattuck Labs Inc. rebound enough to break evenWeekly Market Direction and Sector Summary - Newser
Shattuck Labs - The Pharma Letter
Will breakout in Shattuck Labs Inc. lead to full recoveryAI Short-Term Gain Forecast with Data - Newser
Best Penny Stocks To Consider – August 5th - Defense World
Best Penny Stocks To ConsiderAugust 5th - MarketBeat
Shattuck Labs expects $103 million from private placing - The Pharma Letter
How sentiment analysis helps forecast Shattuck Labs Inc.Volume Based Swing Signal Prediction Map - Newser
Sentiment analysis tools applied to Shattuck Labs Inc.Entry Optimization Guide with Volume Analysis - Newser
Applying Elliott Wave Theory to Shattuck Labs Inc.High Reward Picks with Tight Risk Control - Newser
How hedge fund analytics apply to Shattuck Labs Inc. stock5-Year Price Trend Summary and Analysis - Newser
Shattuck Labs Inc (STTK) Stock: Navigating a Year of Volatility - investchronicle.com
Biotech company lands $103M in new financing - The Business Journals
Shattuck Labs aims to raise $103M; Beijing biotech gets $55M in Series D - Endpoints News
STTK Stock Surge: Time to Strike? - StocksToTrade
Dow Surges Over 100 Points; Pfizer Earnings Top Views - Benzinga
Shattuck Labs stock soars after $103 million private placement By Investing.com - Investing.com Australia
Shattuck Labs stock soars after $103 million private placement - Investing.com
Why Is Shattuck Labs Stock (STTK) Up 35% Today? - TipRanks
Shattuck Labs Announces $103M Private Placement Funding - TipRanks
Shattuck Labs, Inc. Secures Up to $103 Million for Phase 2 Clinical Trials of SL-325 Targeting Autoimmune Diseases - Quiver Quantitative
Shattuck Labs Secures Up To $103M In Private Placement Financing Through Securities Purchase Agreement - 富途牛牛
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):